TCR Engineered Donor T-Cells

A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
75 patients (estimated)
Sponsors
TScan Therapeutics, Inc.
Tags
T Cell (Allogeneic), Adoptive Cellular Therapy, Post-Allogeneic Stem Cell Transplant
Trial Type
Treatment
Last Update
SparkCures ID
1606
NCT Identifier
NCT05473910

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 803-1766

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.